Wave Life Sciences

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Wave Life Sciences reports transformative 2022 with promising clinical advancements

Wave Life Sciences showcased strong clinical progress and financial discipline in Q4 2022.
The collaboration with GSK and advancements in RNA editing and RNAi technologies position Wave for future success.
Despite challenges in increased expenses, Wave's focus on innovative therapies and strategic partnerships bode well for their future.

Wave Life Sciences reports Q1 progress, poised for RNA innovation

Wave Life Sciences showcased strong financial performance, significant program advancements, and a leadership position in RNA editing technology during Q1 2023.
The company's strategic shift, collaboration with GSK, and focus on additional endpoints beyond traditional measures highlight their commitment to innovation and patient outcomes.
While facing challenges in study designs and editing efficiency assessments, Wave's opportunities lie in differentiation, partnerships, and further advancements in precision medicine.

Wave Life Sciences advances RNA editing technology and secures key collaborations

Wave Life Sciences showcased strong progress in RNA editing and clinical programs, bolstered by collaborations and financial stability.
While facing challenges in off-target effects and patient selection, Wave aims to demonstrate leadership in protein restoration through RNA editing.
Anticipated milestones from GSK, advancements in AIMer technology, and upcoming trial data offer promising opportunities for Wave's growth.

Wave Life Sciences reports strong Q3 earnings and advances RNA pipeline

Wave Life Sciences demonstrated financial strength with positive net income and a healthy cash position.
The company's focus on RNA medicine pipeline advancement and collaborations with GSK show promise for future growth.
Challenges lie in addressing questions on program development, treatment functionality, and ensuring treatment efficacy and patient compliance.

Wave Life Sciences reports successful 2023, eyes growth in RNA editing and obesity programs

Wave Life Sciences had a successful year in 2023, with promising advancements in key programs and a stable financial position.
The company faces challenges in managing expenses and meeting high expectations for upcoming clinical data readouts.
However, Wave's strengths lie in its innovative RNA editing technology, diversified pipeline, and collaborations for revenue generation.
Opportunities abound in market differentiation, revenue growth, and addressing unmet medical needs through their unique programs.

Wave Life Sciences reports Q1 loss but shows promise in therapies

Wave Life Sciences is making strides in advancing their therapeutic portfolio with promising clinical trial progress and positive preclinical results.
While facing challenges in program validation and expansion, the company's strong R&D efforts and financial stability position them well for future growth.
With upcoming milestones and a focus on innovative therapies, Wave has opportunities to establish itself as a key player in the biopharmaceutical industry.

Wave Life Sciences reports breakthroughs in RNA editing and clinical progress

Wave Life Sciences showcased a successful quarter with advancements in RNA editing and positive clinical trial outcomes, positioning the company for future growth.
While facing financial challenges, the company's strong cash position and promising pipeline present opportunities for sustained innovation and market expansion.
Navigating regulatory pathways for accelerated approvals and leveraging breakthrough technologies underscore Wave's potential for long-term success in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for

Wave Life Sciences Ltd. (WVE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Wave Life Sciences Enters Oversold Territory

Wave Life Sciences (WVE) news for Monday has WVE stock taking a beating on early data from its Huntington’s disease trial.
The post Wave Life Sciences News: WVE Stock Crashes 50% on Huntington’s Disease Data appeared first on InvestorPlace.

Wave Life Sciences News: WVE Stock Crashes 50% on Huntington’s Disease Data

Wave Life Sciences Ltd. (NASDAQ: WVE) shares dropped sharply to start out the week after the company announced topline data from its ongoing midstage trial in Huntington’s disease.

Is It Over for This Huntington’s Disease Clinical Trial?

Wave Life Sciences stock collapsed Monday after the biotech company's experimental Huntington's disease treatment underperformed a rival drug from Roche and Ionis Pharmaceuticals.
The post Why This Biotech Stock Had Two Devastating Crashes This Month appeared first on Investor's Business Daily.

Why This Biotech Stock Had Two Devastating Crashes This Month

Wipeout In Wave Life Sciences

WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo

Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Wave Life Sciences (WVE) Stock

Wave Life Sciences (WVE) news for Monday about it giving up on a Duchenne muscular dystrophy drug is hitting WVE stock hard.
The post Wave Life Sciences News: WVE Stock Slammed 54% by Duchenne Drug Failure appeared first on InvestorPlace.

Wave Life Sciences News: WVE Stock Slammed 54% by Duchenne Drug Failure

A lack of efficacy in a lead drug candidate is not what investors were expecting.

Here's Why Shares of Wave Life Sciences Are Imploding Today

No change from baseline in dystrophin observed in Phase 1 open-label extension study

Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy

Wave Life Sciences' Suvodirsen May Be Much Better Than Sarepta's Commercialized Eteplirsen, But May Fall Short Of Sarepta's Newer Generation SRP-5051

Suvodirsen is an  investigational stereopure oligonucleotide  in development for the treatment of DMD patients amenable to exon 51 skipping

Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen

Wave leadership to present updates on multiple preclinical programs and discuss advances in PRISM™ platform Wave leadership to present updates on multiple preclinical programs and discuss advances in PRISM™ platform

Wave Life Sciences to Host Analyst and Investor Research Day on October 7, 2019

New independent directors bring deep expertise in drug development, commercial operations and government affairs New independent directors bring deep expertise in drug development, commercial operations and government affairs

Wave Life Sciences Expands Board of Directors with Three New Appointments

CAMBRIDGE, Mass., Aug.  26, 2019  (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference in New York on Monday, September 9, 2019 at 2:50 p.m. ET.

Wave Life Sciences to Present at the Morgan Stanley Global Healthcare Conference

Sarepta Therapeutics

Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.

Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues

Wave Life Sciences (WVE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Small-cap biotech Wave Life Sciences Ltd is once again under pressure Tuesday.

News for Wave Life Sciences Stock (WVE)